These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28195322)

  • 21. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.
    De Simone C; Caldarola G; Maiorino A; Tassone F; Campana I; Sollena P; Peris K
    Dermatol Ther; 2016 Sep; 29(5):372-376. PubMed ID: 27146358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic response modifiers and pediatric psoriasis.
    Bellodi Schmidt F; Shah KN
    Pediatr Dermatol; 2015; 32(3):303-20. PubMed ID: 25727936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent cholestatic jaundice associated with generalized pustular psoriasis: evidence for a neutrophilic cholangitis.
    Allez M; Roux ME; Bertheau P; Erlinger S; Degott C; Morel P; Modigliani R; Rybojad M
    J Hepatol; 2000 Jul; 33(1):160-2. PubMed ID: 10905601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis.
    Tsang V; Dvorakova V; Enright F; Murphy M; Gleeson C
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e117-e119. PubMed ID: 26403378
    [No Abstract]   [Full Text] [Related]  

  • 26. [Generalized pustular psoriasis and cytolytic hepatitis associated with neutrophilic cholangitis].
    Cabanillas M; Pérez-Pérez L; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2006 Jun; 97(5):330-3. PubMed ID: 16956566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitez L
    Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
    [No Abstract]   [Full Text] [Related]  

  • 28. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.
    Saunier J; Debarbieux S; Jullien D; Garnier L; Dalle S; Thomas L
    Dermatology; 2015; 230(2):97-100. PubMed ID: 25471551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
    Tabolli S; Giannantoni P; Paradisi A; Abeni D
    Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
    J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
    Trent JT; Kerdel FA
    Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor necrosis factor-alpha inhibitors for the treatment of psoriasis patients with liver cirrhosis: A report of four cases with a literature review.
    Ergun T; Seckin-Gencosmanoglu D; Salman A; Ozgen Z; Ocak ES; Avsar E; Imeryuz N
    Indian J Dermatol Venereol Leprol; 2017; 83(1):55-59. PubMed ID: 27451931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful treatment with infliximab of sibling cases with generalized pustular psoriasis caused by deficiency of interleukin-36 receptor antagonist.
    Sugiura K; Endo K; Akasaka T; Akiyama M
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):2054-6. PubMed ID: 24910924
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?
    Ingram JR; Anstey AV; Piguet V
    Br J Dermatol; 2012 Oct; 167(4):949-51. PubMed ID: 22486276
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.